REDBIOTEC
Redbiotec is a private biotech company in Zurich-Schlieren. Founded in 2006 as a spin-off of ETH Zürich, the company has won several awards and is backed by experienced institutional and private investors. During its era as a vaccine innovator, Redbiotec has sold its CMV vaccine business to Pfizer in 2015 and also created an HSV-2 immunotherapy. Presently, Redbiotec is dedicated to developing bacteria-based gene therapies to treat cancer and genetic disorders. The proprietary bacteria platform accommodates large and diverse therapeutic cargos and is designed to overcome many delivery hurdles faced by other vehicles.
REDBIOTEC
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2006-11-11
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.redbiotec.ch
Total Employee:
11+
Status:
Closed
Contact:
+41 44 200 23 20
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins Global Site Tag
Current Advisors List
Current Employees Featured
Founder
Investors List
Redalpine
Redalpine investment in Venture Round - Redbiotec
Official Site Inspections
http://www.redbiotec.ch
- Host name: srv127.tophost.ch
- IP address: 194.150.248.44
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "Redbiotec"
Home - Redbiotec AG
We develop and produce key proteins and genetic materials for biopharma and food industry. Industry collaboration is an important pillar of our strategy. With the outlicensing of our HSV-2 …See details»
Company - Redbiotec AG
Redbiotec is a private biotech company in Zurich-Schlieren. Founded in 2006 as a spin-off of ETH Zürich, the company has won several awards, including the renowned W.A. de Vigier Award. …See details»
Leadership - Redbiotec AG
Manages Redbiotec’s operations and growth to scientific leadership in bacterial and protein engineering; Raised > CHF 20 mn capital for the company; Headed the Pfizer deal (Redbiotec Spin-off Redvax sold to Pfizer) Led Redbiotec in …See details»
Redbiotec AG - Swiss Biotech
Having sold its CMV vaccine business to Pfizer in 2015, Redbiotec has since developed potent HSV-2 immunotherapies, and a platform technology of engineered bacteria - BRISPR® - to deliver therapeutic cargos of various …See details»
Redbiotec - Crunchbase Company Profile & Funding
Redbiotec is a private biotech company in Zurich-Schlieren. Founded in 2006 as a spin-off of ETH Zürich, the company has won several awards and is backed by experienced institutional and private investors. During its era as a vaccine …See details»
Redbiotec AG - LinkedIn
Redbiotec is a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. Founded in 2006 as a spin-off of the Swiss Federal Institute of Technology in Zurich (ETH...See details»
Redbiotec AG - Venturelab
Oct 11, 2006 · Redbiotec AG: Redbiotec develops therapeutic bacteria to treat cancer and genetic disorders. Designed to overcome delivery hurdles faced by other vehicles, the proprietary bacteria platform accommodates large and …See details»
Redbiotec AG Company Profile | Schlieren, ZÃœRICH, Switzerland ...
Find company research, competitor information, contact details & financial data for Redbiotec AG of Schlieren, ZÃœRICH. Get the latest business insights from Dun & Bradstreet.See details»
Redbiotec AG | ETH Zurich - ETH Zürich
Redbiotec uses its proprietary rePAX co-expression technology for the efficient generation of multi-component virus-like particles (VLPs) and other protein assemblies. Redbiotec was …See details»
Redbiotec AG - top100startup.ch
Dec 9, 2012 · Redbiotec develops therapeutic bacteria to treat cancer and genetic disorders. Designed to overcome delivery hurdles faced by other vehicles, the proprietary bacteria …See details»
Redbiotec AG - startup.ch
Redbiotec develops therapeutic bacteria to treat cancer and genetic disorders. Designed to overcome delivery hurdles faced by other vehicles, the proprietary bacteria platform accommodates large and diverse therapeutic cargos ranging …See details»
Redbiotec AG - startupticker.ch
Oct 23, 2013 · Redbiotec develops therapeutic bacteria to treat cancer and genetic disorders. Designed to overcome delivery hurdles faced by other vehicles, the proprietary bacteria …See details»
News & Events - Redbiotec AG
Redbiotec AG has entered into a research collaboration and exclusive option agreement with a large-cap pharmaceutical company. The collaboration will leverage Redbiotec’s proprietary …See details»
Contact - Redbiotec AG
Redbiotec AG Wagistrasse 23 8952 Schlieren Switzerland. Tel.: +41 44 738 20 00 Fax: +41 44 738 20 01. [email protected]See details»
Redbiotec Company Profile 2024: Valuation, Funding & Investors
Developer of prophylactic vaccines intended to be used as an immunotherapeutic drug against herpes and cancer.See details»
Redbiotec AG – Swiss Biotech
Having sold its CMV vaccine business to Pfizer in 2015, Redbiotec has since developed potent HSV-2 immunotherapies, and a platform technology of engineered bacteria - BRISPR® - to …See details»
Redbiotec Company Profile - Office Locations, Competitors, …
Redbiotec is a biotech company that develops immunotherapies for cancer and herpes. It creates therapeutic bacteria to deliver RNA and protein. The company focuses on pancreatic cancer …See details»
Careers - Redbiotec AG
We are constantly seeking talented scientists and entrepreneurs to join our team. If you believe that you can contribute to the success of our company, please send your detailed CV to …See details»
Redbiotec AG - VentureRadar
Develops innovative immunotherapies targeting Herpes and cancer using cutting-edge proteins and microorganisms, based on best-in-class technology from a Swiss biotechnology company. …See details»
In the Press - Redbiotec AG
May 27, 2020 · Redbiotec has reached a new inflection point as it progresses two key programs in herpes and cancer. The company’s CEO and CSO explain how it hopes to use bacteria as a …See details»